Literature DB >> 23094329

Mucosal vaccination--an old but still vital strategy.

Henryka Długońska1, Marcin Grzybowski.   

Abstract

The basic premise of vaccinology is to achieve strong protective immunity against defined infectious agents by a vaccine mimicking the effects of natural primary exposure to a pathogen. Because an exposure of humans and animals to microbes occurs mostly through mucosal surfaces, targeting the mucosa seems a rational and efficient vaccination strategy. Many experimental and clinical data confirmed that mucosal immunization offers many advantages over widely used in human and veterinary medicine subcutaneous or intramuscular immunization. In the present article selected aspects regarding mucosal vaccination are discussed. The structure and function of mucosa-associated lymphoid tissue (MALT), comprised of four main mucosal compartments forming a structural and functional unity as well as pivotal cellular MALT components (dendritic and M cells) were briefly characterized. Particular attention was focused on the mode of simple but efficacious delivery of vaccine antigens to mucosal surfaces. A few trials to generate potential mucosal vaccines against toxoplasmosis introduced by nasal or oral routes to experimental animals are also presented.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23094329

Source DB:  PubMed          Journal:  Ann Parasitol        ISSN: 2299-0631


  5 in total

1.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

2.  C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine.

Authors:  Hidehiko Suzuki; Akihiro Watari; Eri Hashimoto; Miki Yonemitsu; Hiroshi Kiyono; Kiyohito Yagi; Masuo Kondoh; Jun Kunisawa
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

Review 3.  Challenges in mucosal HIV vaccine development: lessons from non-human primate models.

Authors:  Iskra Tuero; Marjorie Robert-Guroff
Journal:  Viruses       Date:  2014-08-15       Impact factor: 5.048

Review 4.  Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.

Authors:  Gourapura J Renukaradhya; Balaji Narasimhan; Surya K Mallapragada
Journal:  J Control Release       Date:  2015-09-26       Impact factor: 9.776

Review 5.  Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.

Authors:  Fengling Feng; Ziyu Wen; Jiaoshan Chen; Yue Yuan; Congcong Wang; Caijun Sun
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.